You may experience slightly faster onset of appetite suppression, but this adjustment typically goes unnoticed by most patients
The expression of the growth factor independence1 (Gfi1) transcription factor in Paneth and Goblet cell precursors prevents their conversion into EEC lineage [21]
Because appetite suppression ends, but metabolic inefficiencies remain uncorrected
Evidence in T1D is limited to small, short-term, randomized clinical trials (RCTs) and a few observational studies focusing on surrogate outcomes such as glycemic control and weight loss 8,9,10,11,12
In December 2025, the FDA also expanded the Mounjaro indication to include paediatric patients aged ten and over with type 2 diabetes, following results from the SURPASS-PEDS trial